- Home
- VTGN vs HOTH Comparison
VTGN vs HOTH Comparison
Compare VTGN & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | HOTH |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 17.7M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VTGN | HOTH |
|---|---|---|
| Price | $0.64 | $0.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 546.3K | 358.2K |
| Earning Date | 02-12-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.66 |
| 52 Week High | $5.14 | $2.12 |
Technical Indicators
Market Signals| Indicator | VTGN | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 43.24 |
| Support Level | $0.63 | $0.75 |
| Resistance Level | $0.65 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 69.00 | 7.38 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).